0.00Open0.00Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover258.06%IV55.04%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.3307Delta0.2368Gamma10.32Leverage Ratio-0.0146Theta0.0003Rho3.41Eff Leverage0.0021Vega
Corvus Pharmaceuticals Stock Discussion
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024
Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024
Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefin...
NEWS
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
NEWS
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
No comment yet